$BSOL

Investors Poured $1 Billion Into the Bitwise Solana ETF While It Lost Value. Where BSOL Fits in a Portfolio

The Bitwise Solana Staking ETF (BSOL) reached $1 billion in cumulative inflows, but its value has declined 41% annually, leaving most investors with losses. BSOL offers a 7% staking yield and holds Solana (SOL), but its performance is tied to SOL's price volatility. As of August 24, 2026, its AUM was around $760-$770 million. BSOL captured 66% of US spot Solana ETF inflows on August 27, 2026, reflecting strong distribution rather than valuation.

Original reporting
Published Aug 28, 2026, 4:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 28, 2026, 5:32 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Investors Poured $1 Billion Into the Bitwise Solana ETF While It Lost Value. Where BSOL Fits in a Portfolio — source image
Decision brief

The 30-second read

$BSOLNeutralMed
01

Why it matters

The mismatch between inflows and AUM may drive short‑term price swings and affect allocation decisions for crypto‑focused investors.

02

Market read

BSOL’s inflow milestone and underperformance provide a fresh data point for traders evaluating crypto‑ETF exposure.

03

What to watch

Fee waiver expiration and staking yield limits could further erode returns if SOL stays depressed.

Relevance 6/10Novelty 6/10Timing: late August 2026 recent inflow data

Background

Bitwise’s Solana ETF (BSOL) reached $1 B cumulative inflows while its net asset value fell sharply, prompting a discussion of its role in portfolios.

Company-level read

Ticker impact

$BSOLNeutralMedium confidence
Context

BSOL reported $1.01 B cumulative inflows but AUM fell to $760 M, indicating investors are underwater.

Expected impact

Potential near‑term volatility with upside if inflows continue, downside risk if price stays low.

Evidence & confidence

Large inflow figure is new, but the fund’s price drop is already known; traders may adjust position size.

Market effects

Highlights continued investor interest in single‑asset crypto ETFs despite volatility.

U.S. ETF market sees record inflows to a Solana fund, signaling crypto exposure demand.

Solana’s price move influences broader crypto market sentiment.

Counterpoint

The fund’s poor performance may deter new capital, suggesting a pull‑back rather than continued inflows.

Key entities

  • Bitwise

    Provider of the BSOL ETF.

  • Solana

    Underlying asset of BSOL.

Related articles

$IBITMed

Bitcoin ETFs Lose $56.2M as IBIT Drives 99% of Outflow

U.S. spot Bitcoin ETFs saw $56.2M net outflows on Aug. 14, extending recent withdrawals. According to Farside Investors, BlackRock’s IBIT accounted for $55.5M of redemptions, while Fidelity’s FBTC had $6.8M outflows. Bitwise’s BITB was the only fund with a $6.1M inflow. Ether and Solana ETFs had zero net flows.

$IBITMed

Bitcoin Can't Compete With the AI Trade

Bitcoin fell as iShares Bitcoin Trust (IBIT) dropped more than 5% Tuesday, extending its YTD loss to 23% and marking 11 straight days of outflows totaling $2.6 billion, according to the article. Bitcoin traded near $67,000, down from a $125,000 record. The piece cites debate over Strategy Inc. (MSTR) selling and broader risk appetite shifting to AI, while Ethereum and Solana-linked ETFs also declined.

$CRWDMed

CrowdStrike Shares Pull Back From Highs: The Latest

CrowdStrike (CRWD) shares fell 4.84% to $216.92 after a 20.5% surge following strong Q2 earnings. Revenue was $1.47B, up 26% YoY, with raised full-year guidance. The decline follows SentinelOne's (S) profit guidance cut, sparking sector-wide concerns about growth and margins. CRWD remains up 101% YTD, testing its premium valuation.

$WENMed

Why Wendy's Fell This Week

Wendy's shares fell 9.3% after Trian Fund Management, its largest shareholder, reportedly ruled out a near-term buyout. The stock had risen on speculation of a takeover following disappointing earnings. Wendy's new CEO, Bob Wright, will now lead a turnaround effort. The company has a market cap of $1.49 billion and significant debt.

$AEMDHighAI 8/10

Biotech Gainers: QNRX Leads Gains As AEMD, DWTX And FRNM Report Key Developments

Aethlon Medical (AEMD) reported a 12% narrower Q1 loss and progress in its Hemopurifier study, with shares up 17.5%. Quoin Pharmaceuticals (QNRX) surged 34% pre-market on positive QRX003 data and a $50M financing. Dogwood Therapeutics (DWTX) gained 12% as its Halneuron trial advances. Freenome (FRNM) rose 7% after FDA Breakthrough Device Designation for its lung cancer test.